KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to -$2.3 million.

  • Emergent BioSolutions' Cash from Operations fell 10149.64% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.0 million, marking a year-over-year decrease of 9238.43%. This contributed to the annual value of $58.7 million for FY2024, which is 12845.37% up from last year.
  • According to the latest figures from Q3 2025, Emergent BioSolutions' Cash from Operations is -$2.3 million, which was down 10149.64% from $106.4 million recorded in Q2 2025.
  • Emergent BioSolutions' Cash from Operations' 5-year high stood at $328.1 million during Q4 2021, with a 5-year trough of -$184.0 million in Q1 2023.
  • Over the past 5 years, Emergent BioSolutions' median Cash from Operations value was -$2.3 million (recorded in 2025), while the average stood at $12.2 million.
  • In the last 5 years, Emergent BioSolutions' Cash from Operations plummeted by 83137.25% in 2022 and then surged by 18108.11% in 2023.
  • Over the past 5 years, Emergent BioSolutions' Cash from Operations (Quarter) stood at $328.1 million in 2021, then crashed by 71.72% to $92.8 million in 2022, then tumbled by 65.41% to $32.1 million in 2023, then plummeted by 348.91% to -$79.9 million in 2024, then skyrocketed by 97.12% to -$2.3 million in 2025.
  • Its last three reported values are -$2.3 million in Q3 2025, $106.4 million for Q2 2025, and -$11.2 million during Q1 2025.